Key result
The combination of moderately or severely abnormal LVEF (≤40%) and low-gradient aortic stenosis predicted increased 1-year mortality after TF-TAVI (HR 2.12; 95% CI 1.4-3.2; P<0.001).
Why the study?
The impact of baseline LVEF and its interaction with low-gradient aortic stenosis on all-cause mortality after TF-TAVI needed evaluation.
Does baseline LVEF and the presence of low-gradient aortic stenosis impact 1-year all-cause mortality in patients undergoing TF-TAVI?
Cohort (n=624)
No
Does baseline LVEF and the presence of low-gradient aortic stenosis impact 1-year all-cause mortality in patients undergoing TF-TAVI?
Hazard Ratio: 2.12 (95% CI 1.4–3.2)
p-value: p=< 0.001
Moderately or severely abnormal LVEF (≤40%) combined with low-gradient aortic stenosis (<40 mm Hg) significantly increases 1-year mortality after TF-TAVI, whereas outcomes are comparable in patients with normal or mildly abnormal LVEF regardless of gradient.
Associated with higher post-TF-TAVI mortality; hypothesis-generating for risk stratification in low-gradient AS with reduced LVEF.
OBJECTIVES: To evaluate the impact of baseline left ventricular ejection fraction (LVEF) and its interaction with low-gradient aortic stenosis (LGAS) on all-cause mortality after transfemoral aortic valve implantation (TF-TAVI). METHODS: We reviewed mortality data of 624 consecutive single center TF-TAVI patients and categorized LVEF according to current ASE/EACVI recommendations (normal, mildly-, moderately-, and severely abnormal). RESULTS: Baseline LVEF was normal in 336 (53.8%), mildly abnormal in 160 (25.6%), moderately abnormal in 91 (14.6%), and severely abnormal in 37 (5.9%) patients, and 1-year mortality was 19%, 17%, 23%, and 43% (P = 0.002), respectively. Patients with LGAS had a similar 1-year mortality compared to those without LGAS in groups with normal (19% vs 19%, P = 0.899) and mildly abnormal LVEF (16% vs 17%, P = 0.898). One-year mortality of patients with LGAS was significantly greater than in those without LGAS in presence of moderately abnormal LVEF (31% vs 11%, P = 0.022), and it was numerically greater than in those without LGAS in presence of severely abnormal LVEF (48% vs 25%, P = 0.219). In multivariate analysis, only the combination of moderately/severely abnormal LVEF and LGAS predicted increased 1-year mortality (HR: 2.12, 95% CI: 1.4-3.2, P < 0.001). Other variables, including EuroSCORE I did not affect this result. CONCLUSIONS: Moderately/severely abnormal LVEF (≤40%) at baseline is associated with increased mortality after TF-TAVI, especially when the mean transvalvular aortic gradient is <40 mm Hg (LGAS), while outcomes in patients with normal and mildly abnormal LVEF are comparable regardless of the pressure gradient across the native aortic valve. (DRKS00013729).
No takes yet. Share an insight, caveat, or question.
El‐Chilali et al. (2018) conducted a cohort in Aortic stenosis undergoing transfemoral transcatheter aortic valve implantation (n=624). Moderately/severely abnormal LVEF combined with low-gradient aortic stenosis (LGAS) vs. Normal/mildly abnormal LVEF or absence of LGAS was evaluated on 1-year mortality (HR 2.12, 95% CI 1.4-3.2, p=< 0.001). The combination of moderately or severely abnormal LVEF (≤40%) and low-gradient aortic stenosis predicted increased 1-year mortality after TF-TAVI (HR 2.12; 95% CI 1.4-3.2; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: